Well it annoyed the hell out of me because "completing its development" 3 weeks before Bleepa is launched is not what I want to read. I've worked in IT most of my working life and seeing that phrase so close to a product release is unnerving to say the least. Back in June / July they were beta testing the product in Poland and I'd have hoped all major bugs were out of the system by the end of testing. Only minor, within latest specification stuff should be remaining at that point. That "completing its development " phrase was akin to shooting oneself in the foot and I was angry at seeing it because it contradicted the beta testing in Poland results I'd heard about.
Now, I really don't know whether to blame Andrew Scott or Tom Oakley for it. I can only say that for me it I now have a concern about the product that I didn't have yesterday. They will be complete bâtards if they mess things up at this late stage. The next 3 weeks will have me on tenterhooks.
Here it is. Written by Andrew Scott, the man who interviewed Tom Oakley. Tom either said it to Andrew off camera or he made it up.
"He also touches on the recent well-supported £2mln fundraise which he says will be used for completing its development and building up a sales and support team for when the product is launched next month at NHS Expo in Manchester."
Full article follows.
https://www.proactiveinvestors.co.uk/companies/news/900861/feedback-plc-gearing-up-for-big-launch-of-its-clinical-messaging-product-bleepa-900861.html
Agree with you Chaz. You don't say "the recent well-supported £2mln fundraise... will be used for completing its development" 3 weeks before Bleepa is shown to the public. It should not be completing development at this point. It should have been written with no further changes allowed and that version thoroughly tested by now. FFS they should not be talking about "completing its development". They should be practicing their speech writing and sales pitch from this point onwards.
https://twitter.com/AndrewScottTV/status/1161976815742836737
Simon Eccles - Chief Clinical Information Officer for Health and Care. Deputy CEO NHSX.
https://twitter.com/BleepaMe/status/1160458284496760832
WhatsApp Doc? New device answers SOS.
https://www.businessweekly.co.uk/news/biomedtech/whatsapp-doc-new-device-answers-sos
Sonie, I do believe you are polishing up your ballpark figures. Didn't you have 10-15p yesterday? Stop worrying about it. Nothing we say or do will have a lasting effect here. Que sera sera.
https://www.youtube.com/watch?v=xZbKHDPPrrc
Balaji at the AI in Radiology meeting he attended. Starts talk at 03:30 approx. Note the Siemens Healthineers logo in the background early on.
https://www.expresshealthcare.in/healthcare-videos/radiology-videos/panel-discussion-on-artificial-intelligence-in-radiology-where-are-we-today-rad2024/413031/
All guessing Bob. I don't have time to do more than guess. I'd go for there being around 2 million left on the MM's books. Sounds a lot? Not really. Last time I checked there were 4-5 companies making a book in Feedback. Evenly spread, it would mean around 500k shares for each MM. That can easily go.
Do I think there are more shares to be sold? No. You know who I suspect is behind this and he likes to sell in round numbers until his last trade. Today's trade ended in '548' from memory. I reckon he's done for the time being.
No idea if these shares were 'borrowed' or not but if they were it would explain the lack of holdings RNS whilst accumulation was underway. Personally, I hope they were borrowed because there's a strong likelihood of him making a loss when he is required to hand them back.
Can't think of more to say right now. Hope it helps.
Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: a multicentre retrospective study
https://www.sciencedirect.com/science/article/abs/pii/S0720048X1930261X
Method
One hundred and four patients were enrolled from 3 different centers. CT was performed using similar parameters among different scanners. CTHA was performed with the proprietary software TexRAD, which extracts histogram features at different spatial scale (spatial scale filters, SSF) producing 30 CTHA features per patients. Cross-validated Least Absolute Shrinkage and Selection Operator LASSO was used to select those features which were related to overall and progression-free survival (OS and PFS, respectively). High- and low-risk subgroups were identified using the best cutoff.